Operations Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


OPERATIONS RESEARCH,
Published online in Articles in Advance, July 16, 2008
DOI: 10.1287/opre.1070.0506
This Article
Right arrow Full Text (PDF)
Right arrow e-companion
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Stonebraker, J. S.
Right arrow Articles by Keefer, D. L.

Modeling Potential Demand for Supply-Constrained Drugs: A New Hemophilia Drug at Bayer Biological Products

Jeffrey S. Stonebraker, Donald L. Keefer

Department of Statistics and Operations Technology, Daniels College of Business, University of Denver, Denver, Colorado 80208
Department of Supply Chain Management, W. P. Carey School of Business, Arizona State University, Tempe, Arizona 85287

jeffrey.stonebraker{at}du.edu
don.keefer{at}asu.edu

This paper describes the evolution and application of a novel approach for forecasting drug demand in markets where supply limitations have significantly curtailed sales volumes and thus reduced the usefulness of conventional sales-based forecasting methods. This occurs frequently with biological (biotech) drugs. We use methods from decision analysis to explicitly model the variability in epidemiological data together with the variability in treatment modalities to estimate latent therapeutic demand (LTD)—the underlying demand that captures how physicians would prescribe treatment and how patients would comply if ample supplies of drugs were available and affordable. Our approach evolved from efforts to help Bayer Biological Products with strategic decisions regarding its drug for treating hemophilia A, the future of which had been clouded for several years, primarily due to a lack of confidence in demand estimates. Use of the LTD model resulted in a better understanding of the therapeutic needs of the global hemophilia community and helped Bayer make good decisions. We believe this approach is widely applicable to forecasting potential demand for supply-constrained as well as brand-new drugs, and thus can be very useful in helping both drug manufacturers and health-care agencies worldwide to ensure adequate supplies of critical drugs.

Subject classifications: decision analysis; applications; forecasting; drug demand; industries; pharmaceutical.
History: Received June 2006; revision received September 2007; accepted September 2007.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by INFORMS.